FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.
about
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsBiomarkers predicting antidepressant treatment response: how can we advance the field?Western High-Fat Diet Consumption during Adolescence Increases Susceptibility to Traumatic Stress while Selectively Disrupting Hippocampal and Ventricular VolumesAntidepressant treatment response is modulated by genetic and environmental factors and their interactions.Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective studyUnderstanding the pharmacogenetics of selective serotonin reuptake inhibitors.Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinomaHorizons of psychiatric genetics and epigenetics: where are we and where are we heading?Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome.The Interaction between Childhood Bullying and the FKBP5 Gene on Psychotic-Like Experiences and Stress Reactivity in Real Life.Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational ImplicationsThe FKBP5 Gene Affects Alcohol Drinking in Knockout Mice and Is Implicated in Alcohol Drinking in Humans.Mind and body: how the health of the body impacts on neuropsychiatry.Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism.Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response.FK506 binding protein 51 integrates pathways of adaptation: FKBP51 shapes the reactivity to environmental change.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?The FKBP51 Glucocorticoid Receptor Co-Chaperone: Regulation, Function, and Implications in Health and Disease.Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.Interaction between early-life stress and FKBP5 gene variants in major depressive disorder and post-traumatic stress disorder: A systematic review and meta-analysis.Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder.Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation.Identification and replication of RNA-Seq gene network modules associated with depression severity
P2860
Q26749011-E4331BAF-A484-4383-BC52-CE4D70A8AE43Q27026147-2CCD5627-1CA7-43E2-814B-EFE8FD224D77Q30370012-F865058C-4F2E-407B-9B42-2E887D549884Q33930731-73C3A75C-C387-44F2-A8B2-149F12B5DDF6Q34108860-462EBB85-A266-4554-B229-A1DA32057E32Q34424865-D1441B3E-9BDD-4B1B-AB61-88D1EA138331Q34925232-A3F604BF-8E38-44B6-AEBF-CE161150EA9AQ35177686-D1C0C7AD-F99B-404C-8292-DAA92DAEB4F6Q35953947-B1D37B37-206A-421A-A6E0-9B5EFF10F585Q36070415-21B0FC57-1280-4453-8020-AD5425538CCCQ36366772-F9965045-8CFE-45D9-AC5D-4455470BBCCBQ37210025-EE1A8EE9-357B-42CE-AD41-27FC1F3FCC12Q37399776-951CF1FF-4964-449A-8870-A03B10A7EBF6Q38161940-D3E95579-1987-4B2C-9CA0-DABE1FDC3BEFQ38484370-35F6AB0D-D958-499A-BAB8-A2EFA3F80C43Q38823641-8547F105-288B-4382-BED1-16DAB24AE4BAQ38885066-22ECF432-B22C-4EA1-B6D4-7F4B3BBB12C6Q38983579-60A4408F-098B-4E2F-B79D-AA4B5DF9BC4CQ39171343-1472ADEF-2677-4937-8103-E6A7F6B27FB5Q47329852-70F608B0-E3D1-4F15-85A3-738260AC036EQ47666907-972DA3DC-1AAA-4946-81E5-64059EBAB4F5Q47784282-F37F0296-9A05-4A5F-A2E2-E8363509EE18Q48064738-20DD35CC-5D48-4635-91DC-D61DD83FEFA7Q48241016-45A3DB18-A6E3-4343-BC61-4DFB7FBED220Q58763356-C46CE20F-FCD5-4304-9543-BCAB02E94249
P2860
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
FKBP5 genetic variation: asso ...... in major depressive disorder.
@en
FKBP5 genetic variation: asso ...... in major depressive disorder.
@nl
type
label
FKBP5 genetic variation: asso ...... in major depressive disorder.
@en
FKBP5 genetic variation: asso ...... in major depressive disorder.
@nl
prefLabel
FKBP5 genetic variation: asso ...... in major depressive disorder.
@en
FKBP5 genetic variation: asso ...... in major depressive disorder.
@nl
P2093
P2860
P50
P1476
FKBP5 genetic variation: asso ...... in major depressive disorder.
@en
P2093
Abra Brisbin
Brooke L Fridley
Bruce W Eckloff
David A Mrazek
Eric D Wieben
Gregory D Jenkins
Joanna M Biernacka
Katarzyna A Ellsworth
Liewei Wang
P2860
P304
P356
10.1097/FPC.0B013E32835DC133
P577
2013-03-01T00:00:00Z